Premaitha Health gains traction in Middle East, onboards new customers
International molecular diagnostics group Premaitha Health has clinched several new contracts and customer wins in the Middle East through the company's regional distribution network, increasing the company's potential "addressable market".
FTSE AIM All-Share
753.80
08:40 25/04/24
Pharmaceuticals & Biotechnology
22,694.14
08:40 25/04/24
Yourgene Health
0.52p
17:15 07/09/23
Focused on non-invasive prenatal testing, sometimes referred to as IONA, Premaitha said it secured contracts with three more laboratories in the region, including the UAE and Saudi Arabia.
Those laboratories were expected to start operating with the IONA test by early 2018 while the new customers were to begin sending samples to its service immediately.
Premaitha already had three established customer laboratories in the region prior to Friday's news.
Dr Stephen Little, CEO of Premaitha, emphasised how the company was gaining "growing traction" across the Middle East.
"We are continuing to see growing traction across the Middle East as awareness builds of the benefits of non-invasive prenatal testing, and customers appreciate the benefits of our solution and application support. These latest laboratory contracts should begin to contribute from early 2018 once they become operational. Strategically, the Middle East is another important region in the growth and de-risking of our business through geographic diversification."